Neurotrophic Viral Vector CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage diseases (LSDs) face challenges in effectively delivering therapeutic enzymes across the blood-brain barrier and achieving long-term expression in the central nervous system (CNS), particularly for diseases like Niemann-Pick disease type A, where enzyme replacement therapy is limited due to enzyme cytotoxicity and limited diffusion in the brain.
Innovation Solution
Intraventricular administration of a recombinant neurotrophic viral vector containing a transgene encoding enzymes defective in LSDs, such as acid sphingomyelinase, to favor expression in ependymal cells, allowing for the secretion of therapeutic proteins that can cross-correction and alleviate lysosomal storage pathology in both CNS and visceral organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat lysosomal storage diseases in the CNS, then therapeutic enzymes can be delivered systemically, but the enzymes cannot effectively cross the blood-brain barrier and achieve sufficient expression in the central nervous system
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver therapeutic enzymes across the blood-brain barrier. The viral vectors facilitate transport of the enzyme-gene constructs into CNS cells, overcoming the barrier that prevents direct enzyme delivery. This mediator approach enables the therapeutic enzyme to reach its target destination within the central nervous system.
Solution Approach 2:
The patent replaces the mechanical/physical approach of direct enzyme infusion with a biological delivery system using viral vectors. Instead of relying on passive diffusion or forced convection to deliver enzymes across the blood-brain barrier, the system uses AAV-mediated transduction to achieve cellular uptake and intracellular delivery of therapeutic genes.
2Reliability
If high concentrations of therapeutic enzyme are administered to achieve effective treatment, then metabolic status improves, but enzyme cytotoxicity increases and limits further dosing
Solution Approach 1:
The patent uses AAV vectors to deliver the gene encoding the therapeutic enzyme, establishing long-term, sustained production of the enzyme within CNS cells. This preliminary genetic modification allows the cells to produce the enzyme endogenously over an extended period, avoiding the need for repeated high-dose enzyme administrations that would cause cytotoxicity.
Solution Approach 2:
The therapeutic approach enables the patient's own cells to produce the missing or defective enzyme through AAV-mediated gene transfer. Once the transgene is delivered and integrated, the modified cells continuously synthesize the functional enzyme, creating a self-sustaining therapeutic effect that eliminates the need for external enzyme supplementation and avoids associated toxicity.
3Productivity
If traditional viral vectors are used for CNS gene delivery, then transduction efficiency is improved, but toxicity and immunogenicity increase
Solution Approach 1:
The patent employs adeno-associated virus (AAV) vectors, which have fundamentally different biological parameters compared to traditional viral vectors like adenovirus or herpes simplex virus. AAV vectors replicate in a controlled, non-cytopathic manner, express transgenes at lower but sustained levels, and elicit minimal immune responses. These parameter changes maintain transduction efficiency while dramatically reducing toxicity and immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables a therapeutically effective delivery of enzymes to the CNS and affected organs, significantly improving metabolic status and potentially extending lifespan by reducing substrate accumulation, as demonstrated in animal models, with notable improvements in enzyme activity and survival rates.
Implementation Method 1
The neurons internalize the AAV vector and transport it in a retrograde manner along the axon to the cell body.
Implementation Method 2
These cells may also secrete the therapeutic transgene product, which may be subsequently taken up by distal cells where it may mediate its beneficial effects. This process has been described as cross-correction (Neufeld et al. (1970) Science 169:141-146).
Implementation Method 3
AAV vectors are considered useful for CNS gene therapy because they have a favorable toxicity and immunogenicity profile, are able to transduce neuronal cells, and are able to mediate long-term expression in the CNS
Data Source
AI summary
This disclosure provides methods and compositions for treating lysosomal storage diseases in a subject. In one aspect of the invention, a transgene product is delivered to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject by administering a recombinant neurotrophic viral vector containing the transgene to the subject's brain. The transgene product may be any that is deficient in a lysosomal storage disease.